Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.40 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 4/20 | 0.35 |
| ▸ | GJB2 | P29033 | 1/20 | 0.35 |
| ▸ | LY96 | Q9Y6Y9 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371581 | 1.00 | MAPK1 (0.53) | MAPK1SLC2A1LGALS8LGALS3LGALS4 | |
| SCHEMBL12371571 | 0.89 | TLR4 (0.43) | MAPK1SLC2A1TLR4 | |
| SCHEMBL12560771 | 0.88 | MAPK1 (0.68) | MAPK1SLC2A1LGALS8LGALS3LGALS4 | |
| SCHEMBL12601163 | 0.87 | MAPK1 (0.52) | MAPK1SLC2A1LGALS8LGALS3LGALS4 | |
| SCHEMBL4204252 | 0.84 | MAPK1 (0.52) | MAPK1SLC2A1LGALS8LGALS3LGALS4 | |
| SCHEMBL4204256 | 0.84 | MAPK1 (0.52) | MAPK1SLC2A1LGALS8LGALS3LGALS4 | |
| SCHEMBL23705095 | 0.81 | MAPK1 (0.45) | MAPK1LGALS8LGALS3LGALS4CA1 | |
| SCHEMBL8578436 | 0.81 | MAPK1 (0.45) | MAPK1LGALS8LGALS3LGALS4CA1 | |
| SCHEMBL8578442 | 0.81 | MAPK1 (0.45) | MAPK1LGALS8LGALS3LGALS4CA1 | |
| SCHEMBL12371569 | 0.81 | MAPK1 (0.45) | MAPK1LGALS8LGALS3LGALS4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906633-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-7737129-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | EISAI CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | LIPG, FUT6, UGCG | MAPK1 3870/4885SLC2A1 901/4885LGALS8 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.